A sustainability rule with direct impact for medical devices
From August 2026, the EU’s new Packaging and Packaging Waste Regulation (PPWR) will reshape how products are packaged for the European market. For medical device manufacturers, the regulation is more than an environmental measure. It introduces binding packaging obligations that must be managed alongside sterile-barrier performance, product safety and compliance with the medical devices regulations (MDR and IVDR).
What applies from 12 August 2026?
The first major compliance date was 12 August 2026. From that date, each packaging type placed on the EU market for the first time will need an EU declaration of conformity and supporting technical documentation. The documentation should demonstrate how the packaging meets the relevant PPWR requirements.
Substance limits for lead, cadmium, mercury and hexavalent chromium apply. The regulation also places restrictions on intentionally added PFAS in food-contact packaging, while broader EU scrutiny of substances of concern remains relevant for medical device packaging strategies. Importantly, packaging lawfully placed on the EU market before the application date can generally remain on the market. The new obligations attach to packaging placed on the market from the application date forward.
Limited relief for contact-sensitive packaging
Contact-sensitive primary packaging, such as sterile-barrier trays, pouches and multilayer films, benefits from limited exemptions from recyclability performance grades and minimum recycled-content targets. However, that relief is not a carve-out. Documentation, conformity assessment, substance restrictions, extended producer responsibility (EPR), labelling and packaging-minimisation duties still apply unless a specific exemption is available.
Classification will be the sleeper risk
The practical challenge is proving which packaging qualifies for relief. There is no simple official test for “contact-sensitive” packaging. Each packaging layer should be assessed on its function and intended use. For manufacturers, the best protection is a clear paper trail. Assessments should record the packaging level, its function, whether it is in direct contact with the device, why an exemption is or is not relied on, and what evidence supports the conclusion.
Why the timeline is tight for medical device manufacturers
Packaging changes in the medical device sector are rarely simple. A thinner pouch, new material or smaller carton may trigger risk assessment, packaging validation, sterilisation compatibility review, shelf-life evaluation, transport testing, production-line changes and updates to technical documentation. That means PPWR planning should not wait until sustainability or labelling deadlines arrive. Even where later obligations phase in through 2030, 2035 and 2040, the groundwork starts with today’s packaging portfolio and validation constraints.
Source: Medtech Insight (an Informa product)





